Quest for Novel Preventive and Therapeutic Options Against Multidrug-Resistant

Sidra Irum, Saadia Andleeb, Amjad Ali, Muhammad Ibrahim Rashid, Mahnoor Majid

Open access · bronzeAbstract read

In one paragraph

Article in International journal of peptide research and therapeutics, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it

0cells of the map it votes in

3citing papers in PubMed

0.3field-weighted citation impact, top 44% of its field

1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 5 citations in OpenAlex.

Subtractive Proteomic Approaches to Identify Drug Targets: An Analysis on Hypothetical Proteins of Multidrug-ResistantACS omega · 2025
Article
A computational approach to developing a multi-epitope vaccine for combating Pseudomonas aeruginosa-induced pneumonia and sepsis.Briefings in bioinformatics · 2024
Article
Improving Protection to Prevent Bacterial Infections: Preliminary Applications of Reverse Vaccinology against the Main Cystic Fibrosis Pathogens.Vaccines · 2023
Review

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 2 institutions in 1 country.

Sidra IrumDepartment of Industrial Biotechnology, Atta-ur-Rahman School of Applied Biosciences (ASAB), National University of Science & Technology (NUST), Sector H-12, Islamabad, 44000 Pakistan.

Saadia AndleebDepartment of Industrial Biotechnology, Atta-ur-Rahman School of Applied Biosciences (ASAB), National University of Science & Technology (NUST), Sector H-12, Islamabad, 44000 Pakistan.ORCID 0000-0001-5426-4712

Amjad AliDepartment of Industrial Biotechnology, Atta-ur-Rahman School of Applied Biosciences (ASAB), National University of Science & Technology (NUST), Sector H-12, Islamabad, 44000 Pakistan.

Muhammad Ibrahim RashidDepartment of Industrial Biotechnology, Atta-ur-Rahman School of Applied Biosciences (ASAB), National University of Science & Technology (NUST), Sector H-12, Islamabad, 44000 Pakistan.

Mahnoor MajidDepartment of Industrial Biotechnology, Atta-ur-Rahman School of Applied Biosciences (ASAB), National University of Science & Technology (NUST), Sector H-12, Islamabad, 44000 Pakistan.

National University of Sciences and Technology · PKKhyber Medical University · PK

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1007/s10989-021-10255-3.

Indexed as

Chimeric vaccineDruggable targetsPseudomonas aeruginosaReverse vaccinologySubtractive proteomicsVaccine candidates

Identifiers

PMID34393689

DOI10.1007/s10989-021-10255-3

PMCPMC8351238

OpenAlexW3191410741

What OpenQuestion holds

Textmetadata

Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.